Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 596
Last updated 2026-04-16
Summary
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Conditions
Interventions
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Pemetrexed
Specified dose on specified days
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-05
- Primary Completion
- 2028-09-15
- Completion
- 2031-05-15
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Belgium
- Canada
- Chile
- China
- Colombia
- France
- Germany
- Greece
- India
- Italy
- Japan
- Mexico
- Netherlands
- Norway
- Poland
- Romania
- Singapore
- South Korea
- Spain
- Switzerland
- Taiwan
- Thailand
- United Kingdom
Study Locations
More Related Trials
-
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
NCT06110663 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
NCT03802240 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
NCT03667820 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
NCT05153408 ·Status: TERMINATED ·Phase: PHASE1
-
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2
-
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
NCT02803203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
NCT06380348 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
NCT07109531 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
NCT06688656 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076 ·Status: RECRUITING ·Phase: PHASE2
-
Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma
NCT02518802 ·Status: UNKNOWN ·Phase: PHASE3
-
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
NCT02001896 ·Status: UNKNOWN ·Phase: PHASE3
-
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084 ·Status: ACTIVE_NOT_RECRUITING
-
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT05015608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
NCT06281964 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
NCT04971187 ·Status: TERMINATED ·Phase: PHASE2
-
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
NCT00903292 ·Status: UNKNOWN ·Phase: NA
-
NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer
NCT00994097 ·Status: COMPLETED ·Phase: PHASE2
-
Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
NCT02066038 ·Status: UNKNOWN ·Phase: PHASE2
-
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
NCT06334757 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
NCT04606771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
NCT02876081 ·Status: WITHDRAWN ·Phase: PHASE2
-
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NCT06956001 ·Status: RECRUITING ·Phase: PHASE3
-
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
NCT01565538 ·Status: COMPLETED ·Phase: PHASE2